Shanghai Realway Capital Asset Competitors and Similar CompaniesClear all

Shanghai Realway Capital Asset's competitors and similar companies include Wahed Invest, Erste Asset Management, CriticalPoint Partners and HealthCare Royalty.
Shanghai Realway Capital Asset
Shanghai Realway Capital Asset
Shanghai Realway Capital Asset (上海瑞威资产管理股份有限公司) is a provider of investment management services.
Wahed Invest
Wahed Invest
Wahed is an automated ethical investment platform.
Erste Asset Management
Erste Asset Management
Erste Asset Management is an asset management firm.
CriticalPoint Partners
CriticalPoint Partners
CriticalPoint Partners is an advisory and investment banking firm focusing on mergers and acquisitions (M&A) advisory solutions.
HealthCare Royalty
HealthCare Royalty
HealthCare Royalty Partners is an investment firm that purchases royalties and invests in commercial or near-commercial stage biopharmaceutical assets.
Founding Date
Founding Date
2010
Founding Date
2015
Founding Date
2008
Founding Date
2012
Founding Date
2021
Type
Type
Private
Type
Private
Type
Private
Type
Private
Type
Private
Tags
Locations
Locations
HQ
Locations
New York, US HQ
Locations
Wien, AT HQ
Locations
Manhattan Beach, US HQ
Locations
Stamford, US HQ
London, GB
Boston, US
San Francisco, US
Employees
Employees
N/A
Employees
1983% increase
Employees
256
Employees
658% increase
Employees
33
For sources of this data, please see the company profile

View Company Profiles

Wahed Invest
HQ
New York, US
Employees
198↑ 3% increase

Wahed is an automated ethical investment platform.

View company
Erste Asset Management
HQ
Wien, AT
Employees
256

Erste Asset Management is an asset management firm.

View company
CriticalPoint Partners
HQ
Manhattan Beach, US
Employees
65↑ 8% increase

CriticalPoint Partners is an advisory and investment banking firm focusing on mergers and acquisitions (M&A) advisory solutions.

View company
HealthCare Royalty
HQ
Stamford, US
Employees
33

HealthCare Royalty Partners is an investment firm that purchases royalties and invests in commercial or near-commercial stage biopharmaceutical assets.

View company